Wyeth Again Fails To Detail Pristiq Sales

Wyeth yesterday announced its second quarter results and once again failed to detail sales of its new and heavily-advertised anti-depressant Pristiq. The company only noted in its announcement that the drug had "higher sales," but offered no sales data. That's better than earlier this year when the drug hardly garnered a mention in earlier financial reports.

What this means is that the metabolite of Effexor--which rang up over 700 million in sales in the second quarter--isn't generating enough sales figures to even be worth mentioning to investors. So much for the creepy wind-up doll ads.